Sonnet BioTherapeutics Holdings shares are trading higher after EF Hutton initiated a Buy rating on the stock and announced a $6.70 price target.
Portfolio Pulse from Benzinga Newsdesk
Sonnet BioTherapeutics Holdings shares are trading higher after EF Hutton initiated a Buy rating on the stock and announced a $6.70 price target.
May 25, 2023 | 3:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sonnet BioTherapeutics' stock price is trading higher after EF Hutton initiated a Buy rating and set a $6.70 price target.
The Buy rating and $6.70 price target set by EF Hutton for Sonnet BioTherapeutics Holdings directly impacts the stock price, causing it to trade higher. The positive rating from a reputable financial institution increases investor confidence and demand for the stock, leading to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100